MP
MREO

Mangrove Partners’s Mereo BioPharma MREO Stock Holding History

Mangrove Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,790,580
Closed -$16M – 415
2025
Q3 		$16M Sell
7,790,580
-845,905
-10% -$1.56M 1.19% 25
2025
Q2 		$23.4M Hold
8,636,485
– – 2.51% 15
2025
Q1 		$19.4M Hold
8,636,485
– – 2.1% 16
2024
Q4 		$30.2M Sell
8,636,485
-93,235
-1% -$366K 3.34% 9
2024
Q3 		$35.9M Sell
8,729,720
-23,173
-0.3% -$95.9K 3.08% 9
2024
Q2 		$31.5M Hold
8,752,893
– – 2.42% 13
2024
Q1 		$28.9M Hold
8,752,893
– – 2.01% 15
2023
Q4 		$20.2M Buy
8,752,893
+3,221,346
+58% +$6.16M 1.37% 22
2023
Q3 		$7.14M Hold
5,531,547
– – 0.54% 62
2023
Q2 		$7.3M Buy
+5,531,547
New +$6.42M 0.51% 58

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Mangrove Partners's MREO Position: Q4 2025 in Review

Mangrove Partners sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 7,790,580 shares — an estimated $16M sold.

Mangrove Partners first reported a position in MREO in Q2 2023 and held it in 10 quarters. The position peaked at $35.9M in Q3 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Mangrove Partners reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Mangrove Partners sold 7,790,580 Mereo BioPharma shares in Q4 2025, an estimated $16M.
  • Mangrove Partners first reported a position in Mereo BioPharma in Q2 2023 and held it in 10 quarters.
  • Mangrove Partners's Mereo BioPharma position peaked at $35.9M in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Mangrove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.